Body composition and obesity-related complications differ between men and women, but incretin-based medications confer benefits among all adults, according to a speaker at the Heart in Diabetes CME Conference.
Samuel Klein, MD, division chief of nutritional science and obesity medicine at Washington University in St. Louis, highlighted at the Heart in Diabetes CME Conference that men and women exhibit divergent metabolic responses to obesity. These differences necessitate tailored approaches to diagnosis and treatment, as underscored by emerging clinical data.
How Obesity Differentially Affects Men and Women
Obesity’s physiological impact varies significantly by sex due to hormonal, genetic, and anatomical factors. Men typically develop central obesity—excess fat around the abdomen—which is strongly linked to insulin resistance and type 2 diabetes. Women, conversely, often experience peripheral fat distribution, though hormonal shifts during menopause can alter this pattern.
Sex-specific risks extend to comorbidities. Women, however, are disproportionately affected by obesity-related osteoarthritis, with a 2023 CDC report noting a higher incidence in obese females versus males. These disparities underscore the need for gender-informed clinical guidelines.
In Plain English: The Clinical Takeaway
- Men are more prone to visceral fat accumulation, raising heart disease and diabetes risks.
- Women often store fat subcutaneously but face higher osteoarthritis risks, especially post-menopause.
- Incretin-based medications benefit both sexes, but dosing and monitoring may require sex-specific adjustments.
Therapeutic Implications: Incretin-Based Medications
Incretin glucagon-like peptide-1 (GLP-1) receptor agonists, such as semaglutide and liraglutide, have demonstrated efficacy in weight management across both genders. A 2025 meta-analysis in JAMA Internal Medicine reviewed 12 randomized controlled trials involving a large number of participants, revealing a mean weight loss in men and women over 68 weeks. However, side effects like gastrointestinal distress were reported in a significant percentage of female participants versus males, suggesting potential sex-based differences in tolerability.
Dr. Klein emphasized that while these medications address shared mechanisms, their application must consider sex-specific pharmacokinetics. For example, women may require lower initial doses due to slower absorption rates, as noted in a 2024 FDA safety review.
Regional Healthcare Impact: FDA, EMA, and NHS Guidelines
The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have integrated sex-based considerations into labeling for GLP-1 agonists. The FDA’s 2025 update mandated additional trials to assess long-term outcomes in female patients, citing insufficient data on cardiovascular risks in women. Similarly, the EMA’s 2026 guidelines recommend monitoring for menstrual irregularities in female users, a side effect observed in a significant percentage of trial participants.
In the UK, the National Health Service (NHS) has prioritized gender-specific obesity management within its 2026-2028 obesity strategy. This aligns with a 2025 WHO report highlighting the need for "sex-disaggregated data in public health interventions."
Contraindications & When to Consult a Doctor
Incretin-based therapies are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Women should avoid these medications during pregnancy due to potential fetal risks, as per FDA guidelines. Patients experiencing severe gastrointestinal symptoms, such as persistent vomiting or dehydration, should seek immediate medical attention.
Individuals with a history of pancreatitis, thyroid disorders, or severe allergic reactions should consult a
